中国P站

Endometrial Cancer; Carcinogenesis; Hormonal Imbalances; Genetic Mutations; Epigenetic Alterations; Tumor Microenvironment; Genomic Instability; Molecular Subtypes; PI3K/AKT/mTOR Pathway; MicroRNAs

Introduction

Endometrial carcinogenesis is a multifaceted process initiated by hormonal imbalances, genetic mutations, and epigenetic alterations, representing a significant area of oncological research [1].

Estrogen, unopposed by progesterone, acts as a primary driver, fostering endometrial cell proliferation and inducing DNA damage, which are foundational events in the development of cancer [6].

Key molecular signaling pathways intricately involved in this process include those governed by PI3K/AKT, WNT/beta-catenin, and TGF-beta, highlighting the complex cellular mechanisms at play [1].

The progression from normal endometrial tissue to hyperplasia and subsequently to carcinoma is characterized by the gradual accumulation of genetic and epigenetic changes, leading to distinct molecular subtypes such as endometrioid and serous carcinomas, each with unique etiological and prognostic implications [1].

Epigenetic modifications, including DNA methylation and histone modifications, play a crucial role in the initiation and progression of endometrial cancer by altering gene expression patterns [3].

Aberrant methylation can lead to the silencing of essential tumor suppressor genes or the activation of oncogenes, thereby contributing to neoplastic transformation [3].

These epigenetic alterations are often among the earliest events in tumorigenesis and possess potential as valuable biomarkers for early detection and prognosis [3].

Genomic profiling and the analysis of mutational signatures have facilitated the identification of distinct molecular subtypes of endometrial cancer, namely POLE-mutated, mismatch repair-deficient (MMRd), copy-number-low (CNS-low), and copy-number-high (CNS-high) [4].

These classifications are critical as they exhibit differing clinical behaviors and therapeutic vulnerabilities, emphasizing the imperative for personalized treatment strategies based on precise molecular subtyping [4].

Genomic instability, encompassing both microsatellite instability (MSI) and chromosomal instability (CIN), is another significant contributor to endometrial carcinogenesis [10].

MSI, particularly prevalent in endometrioid endometrial cancers, is associated with a more favorable prognosis and a heightened response to immunotherapy [10].

Conversely, CIN is more frequently observed in aggressive subtypes such as serous carcinoma, indicating different underlying genomic mechanisms [10].

The tumor microenvironment, a complex ecosystem comprising immune cells, stromal components, and the extracellular matrix, profoundly influences endometrial cancer progression and its response to therapeutic interventions [2].

A comprehensive understanding of these intricate interactions is vital for the development of innovative immunotherapies and targeted treatment modalities [2].

The dynamic interplay between cancer cells and their surrounding milieu significantly dictates tumor growth, metastatic potential, and the capacity for immune evasion [2].

Chronic inflammation and infections, particularly those involving certain oncogenic viruses like HPV, can also contribute to endometrial carcinogenesis by creating a pro-tumorigenic environment [5].

Inflammatory mediators can stimulate cell proliferation, promote angiogenesis, and induce DNA damage, thereby fostering the conditions necessary for tumor development [5].

Identifying these contributing factors is essential for the implementation of effective preventive strategies [5].

Hormonal factors, most notably prolonged exposure to unopposed estrogen, are foundational to the pathogenesis of endometrioid endometrial cancer [6].

This hormonal influence can lead to endometrial hyperplasia, a recognized precursor lesion that may subsequently progress to cancer through the accumulation of genetic and epigenetic alterations [6].

Recognizing this hormonal dependency is paramount for accurate risk stratification and effective clinical management [6].

The aberrant activation of the PI3K/AKT/mTOR signaling pathway is a recurrent event in endometrial cancer, significantly promoting cell growth, survival, and resistance to apoptosis [9].

This pathway is frequently altered through genetic mutations in genes such as PTEN and PIK3CA, or via gene amplification, establishing it as a principal target for therapeutic interventions [9].

MicroRNAs (miRNAs), which are small non-coding RNAs crucial for gene expression regulation, are often dysregulated in endometrial cancer and can function as either oncogenes or tumor suppressors [8].

Their dysregulation impacts multiple stages of carcinogenesis, including cellular proliferation, invasion, and metastasis, positioning miRNAs as potential diagnostic and prognostic biomarkers [8].

Furthermore, the metabolic reprogramming within endometrial cancer cells is increasingly acknowledged as a critical factor in their rapid proliferation and survival strategies, exemplified by enhanced glycolysis [7].

Exploiting these metabolic dependencies presents a promising avenue for novel therapeutic interventions [7].

Description

Endometrial carcinogenesis is a complex process driven by a confluence of hormonal imbalances, genetic mutations, and epigenetic alterations [1].

The unopposed action of estrogen, without the counterbalancing effect of progesterone, serves as a primary instigator, promoting endometrial cell proliferation and contributing to DNA damage, thereby initiating the cascade towards malignancy [6].

Integral to this process are key molecular pathways, including those regulated by PI3K/AKT, WNT/beta-catenin, and TGF-beta, which orchestrate critical cellular functions [1].

The transition from healthy endometrial tissue to hyperplasia and finally to carcinoma involves a stepwise accumulation of genetic and epigenetic modifications, ultimately defining distinct molecular subtypes of endometrial cancer, such as endometrioid and serous carcinomas, each with unique etiological origins and prognostic trajectories [1].

Epigenetic mechanisms, including DNA methylation patterns and histone modifications, play a pivotal role in the genesis of endometrial cancer by influencing gene expression [3].

Disruptions in methylation can result in the silencing of tumor suppressor genes or the activation of oncogenes, thereby facilitating neoplastic transformation [3].

These epigenetic changes are often observed early in the tumorigenic process and hold promise as valuable biomarkers for clinical applications [3].

Through comprehensive genomic profiling and the analysis of mutational signatures, distinct molecular subtypes of endometrial cancer have been identified, including POLE-mutated, mismatch repair-deficient (MMRd), copy-number-low (CNS-low), and copy-number-high (CNS-high) [4].

These classifications are clinically significant due to their differential clinical behaviors and therapeutic susceptibilities, underscoring the importance of personalized treatment approaches tailored to specific molecular profiles [4].

Genomic instability, manifested as microsatellite instability (MSI) and chromosomal instability (CIN), significantly contributes to endometrial carcinogenesis [10].

MSI is particularly prominent in endometrioid endometrial cancers and is associated with improved prognosis and a better response to immunotherapy [10].

In contrast, CIN is more frequently observed in aggressive subtypes like serous carcinoma, indicating distinct underlying genomic mechanisms [10].

The tumor microenvironment, comprising immune cells, stromal components, and the extracellular matrix, plays a critical role in modulating endometrial cancer progression and its response to therapy [2].

A thorough understanding of these interactions is essential for the development of novel immunotherapies and targeted treatment strategies [2].

The dynamic interplay between cancer cells and their surrounding milieu significantly influences tumor growth, metastatic potential, and immune evasion mechanisms [2].

Chronic inflammation and certain infections, particularly those involving oncogenic viruses like HPV, can contribute to endometrial carcinogenesis by fostering a pro-tumorigenic environment [5].

Inflammatory mediators can promote cell proliferation, angiogenesis, and DNA damage, thereby creating conditions conducive to tumor development [5].

Identifying these contributing factors is crucial for the implementation of effective preventive measures [5].

Hormonal influences, especially prolonged exposure to unopposed estrogen, are fundamental to the pathogenesis of endometrioid endometrial cancer [6].

This hormonal stimulus can lead to endometrial hyperplasia, a precursor lesion that may progress to cancer through the accumulation of genetic and epigenetic alterations [6].

Comprehending this hormonal dependency is vital for accurate risk stratification and optimal clinical management [6].

The aberrant activation of the PI3K/AKT/mTOR signaling pathway is a common occurrence in endometrial cancer, driving cell growth, survival, and resistance to apoptosis [9].

This pathway is frequently dysregulated via gene mutations (e.g., PTEN, PIK3CA) or amplification, making it a significant target for therapeutic interventions [9].

MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression, are frequently dysregulated in endometrial cancer and can act as oncogenes or tumor suppressors [8].

Their dysregulation impacts various stages of carcinogenesis, including proliferation, invasion, and metastasis, and they hold potential as diagnostic and prognostic biomarkers [8].

Moreover, metabolic reprogramming within endometrial cancer cells is increasingly recognized for its role in supporting rapid proliferation and survival, notably through increased glycolysis [7].

Targeting these metabolic vulnerabilities represents a promising therapeutic strategy [7].

Conclusion

Endometrial cancer development is a complex process involving hormonal imbalances, genetic mutations, and epigenetic alterations, with estrogen unopposed by progesterone being a key driver [1, 6]. Essential molecular pathways like PI3K/AKT, WNT/beta-catenin, and TGF-beta are implicated [1].

The progression from normal endometrium to carcinoma involves accumulating genetic and epigenetic changes, leading to distinct molecular subtypes with varying prognoses [1, 4]. Epigenetic modifications, such as DNA methylation, play a crucial role and can serve as biomarkers [3].

Genomic instability, including MSI and CIN, also contributes significantly [10].

The tumor microenvironment, inflammation, and chronic infections can influence cancer progression [2, 5]. Hormonal factors, particularly estrogen exposure, are central to endometrioid endometrial cancer pathogenesis [6].

The PI3K/AKT/mTOR pathway is frequently activated and a therapeutic target [9].

MicroRNAs (miRNAs) are dysregulated and have biomarker potential [8].

Metabolic reprogramming within cancer cells, such as increased glycolysis, presents therapeutic opportunities [7].

References

1. Timothy RW, Joakim Ö, Kenneth WT. (2022) .Nat Rev Cancer 22:1001-1014.

   , ,

2. Young JC, Haeri K, Sun-Hee K. (2023) .J Gynecol Oncol 34:e17.

   , ,

3. Fumiko H, Yosuke M, Kenji B. (2021) .Epigenomics 13:1443-1458.

   , ,

4. Eliezer MVA, David MW, Yasin RY. (2022) .N Engl J Med 386:1059-1070.

   , ,

5. Chiara F, Antonella T, Mauro T. (2021) .Front Oncol 11:688994.

   , ,

6. Francesca DN, Paola LM, Anna RG. (2022) .J Steroid Biochem Mol Biol 216:106079.

   , ,

7. Zhen-yu L, Yan-yan W, Xiao-hong S. (2023) .Cancer Metab 11:10.

   , ,

8. Shu-Ling Z, Lei Y, Xiao-Li Y. (2021) .J Med Genet 58:877-887.

   , ,

9. Laura MKM, Kathryn SAC, Michael JB. (2022) .Expert Opin Ther Targets 26:1089-1100.

   , ,

10. Daphne AT, Priyanka DS, Usha LG. (2021) .Gynecol Oncol 163:241-251.

    , ,